Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

ALXO

ALXO News

Newswire

09:51

Precision Oncology Sector Sees Transformation with Biomarker-Driven Therapies and Immunotherapies.

04:37

ALX Oncology Holdings' Price Target Increased by 12.50% to $3.06

15:58

ALX Oncology Holdings Q3 2025 Earnings Call Transcript: Evorpacept Data Validates CD47 Biomarker in HER2-Positive Gastric Cancer, ALX2004 ADC Enters Clinic

15:58

ALX Oncology Forecasts $2B-$4B HER2/CD47 Breast Cancer Market Opportunity

15:21

ALX Oncology shares surge 16.10% intraday after ASPEN-06 trial shows evorpacept efficacy in HER2+ gastric cancer with high CD47 expression.

View More

About ALXO

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More